News

News and Press Releases
Patient Assistance | Research Journal of CF Highlights Cost Burden Prevalent in the Cystic Fibrosis Community

Two-thirds of people with cystic fibrosis in the U.S. experience debt, food insecurity, or housing issues.

| 4 min read
Research Simplify Study Indicates Potential to Reduce Medication Burden for People With CF Taking Trikafta

Results show that people on Trikafta® enrolled in the six-week study were able to safely stop taking one of the two common CF medications without negatively affecting their health.

| 4 min read
Research CF Foundation and Bakar Labs Announce Winners of First-Ever Golden Ticket Competition

The Foundation and Bakar Labs will support AVECRIS Pte Ltd and Nosis Biological Sciences as they pursue genetic therapies for cystic fibrosis with their novel technologies.

| 4 min read
Lung Transplantation | Research CF Foundation Awards $1.6 Million to Improve Detection of Lung Transplant Complication

The studies aim to improve early detection of chronic lung allograft dysfunction (CLAD), the leading cause of lung transplant failures.

| 5 min read
Research Cystic Fibrosis Foundation Strikes First-of-Its-Kind Deal With Pioneering Medicines, a Flagship Pioneering Initiative

Foundation to fund up to $110 million for collaboration to accelerate the development of genetic therapies for CF

| 4 min read
Our Research Approach | Patient Registry | Research CF Foundation Launches Lung Transplant Biorepository and Patient Registry

The Cystic Fibrosis Lung Transplant Consortium Biorepository and Patient Registry, in collaboration with Cleveland Clinic, will provide critical clinical data and samples to support future research investigating complications of lung transplant.

| 4 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Funds Three New Research Awards to Advance its Path to a Cure Initiative

New funding awards include up to $2.6M to Eloxx Pharmaceuticals to identify potential therapies for CF nonsense mutations

| 5 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Invests Up to $8.4M in SpliSense for the Development of Potential Rare Mutation Therapy

Today, the Cystic Fibrosis Foundation announced that it will invest up to $8.4 million in SpliSense's Series B funding round to develop an antisense oligonucleotide therapy for people with cystic fibrosis who have splicing mutations and potentially other rare mutations.

| 4 min read
Research Molecular Analysis Identifies Key Differences in Lungs of People With Cystic Fibrosis

Researchers' catalog of airway cell types could reveal targets for future genetic therapies

| 6 min read